Recent clinical trials have explored various amylin analogs, including pramlintide, cagrilintide, davalintide (AC2307) and GUBamy (GUB014295), that have demonstrated potential in addressing overweight and/or obesity due to their actions as leptin sensitizers [47,171] (Table 1). Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.